Northwest Biotherapeutics (Northwest Biotherapeutics) Accounts Receivable : $0.00 Mil (As of Mar. 2024)

View and export this data going back to 2001. Start your Free Trial

What is Northwest Biotherapeutics Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Northwest Biotherapeutics's accounts receivables for the quarter that ended in Mar. 2024 was $0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Northwest Biotherapeutics's Days Sales Outstanding for the quarter that ended in Mar. 2024 was 0.00.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Northwest Biotherapeutics's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $-0.08.

Northwest Biotherapeutics Accounts Receivable Historical Data

The historical data trend for Northwest Biotherapeutics's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Northwest Biotherapeutics Accounts Receivable Chart

Northwest Biotherapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Receivable

Get a 7-Day Free Trial

Northwest Biotherapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Receivable	Get a 7-Day Free Trial															-	-	-	-	-

Northwest Biotherapeutics Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Northwest Biotherapeutics Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Northwest Biotherapeutics's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0.284	*	91
=	0.00

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Northwest Biotherapeutics's accounts receivable are only considered to be worth 75% of book value:

Northwest Biotherapeutics's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(2.478	+	0.75 * 0	+	0.5 * 0	-	101.849
-	0	-	0)	/	1195.36
=	-0.08

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Northwest Biotherapeutics Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Northwest Biotherapeutics's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Northwest Biotherapeutics (Northwest Biotherapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Northwest Biotherapeutics Inc (OTCPK:NWBO) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

NBYB:Germany

Address

4800 Montgomery Lane, Suite 800, Bethesda, MD, USA, 20814

Website

https://www.nwbio.com

Northwest Biotherapeutics Inc is a biotechnology company involved in the development of cancer vaccines. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S. Food and Drug Administration.

Executives

Navid Malik	director	1 CHOLMELEY PARK, HIGHGATE, LONDON X0 N6 5ET
Marnix L Bosch	officer: Chief Technical Officer	22322 20TH AVENUE SE, STE 250, BOTHELL WA 98021
Alton L Boynton	director, officer: Chief Scientific Officer	22322 20TH AVENUE SE, STE 150, BOTHELL WA 98021
Leslie J. Goldman	officer: See Remarks	C/O NORTHWEST BIOTHERAPEUTICS, INC., 4800 MONTGOMERY LANE, SUITE 800, NEW YORK NY 20814
Linda F Powers	director, 10 percent owner, officer: President and CEO	7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814
Jerry J Jasinowski	director	C/O HARSCO CORP, P O BOX 8888, CAMP HILL PA 17001-8888
Jean M. Davis	officer: See Remarks	4800 MONTGOMERY LANE, SUITE 800, BETHESDA MD 20814
Susan B Bayh	director	WELLPOINT, INC., 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204
Black Cofer	director	4800 MONTGOMERY LANE, SUITE 800, BETHESDA MD 20814
Woodford Investment Management Llp	10 percent owner	27 OLD GLOUCESTER STREET, LONDON X0 WC1N 3AX
Cf Woodford Equity Income Fund	10 percent owner	C/O WOODFORD INVESTMENT MANAGEMENT LTD, 9400 GARSINGTON ROAD, OXFORD X0 OX4 2HN
Cognate Bioservices, Inc.	10 percent owner	7513 CONNELLEY DRIVE, HANOVER MD 21076
Robert A Farmer	director	10205 COLLINS AVE PENTHOUSE 6, MIAMI BEACH FL 33154
Toucan General Ii, Llc	10 percent owner	7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814
Hemphill Robert F Jr.	10 percent owner	7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814